VanEck Pharmaceutical ETFPPH
PPH
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
3% more capital invested
Capital invested by funds: $508M [Q4 2024] → $526M (+$17.6M) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
5% less funds holding
Funds holding: 137 [Q4 2024] → 130 (-7) [Q1 2025]
9.02% less ownership
Funds ownership: 86.53% [Q4 2024] → 77.51% (-9.02%) [Q1 2025]
24% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 25
28% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 47
97% less call options, than puts
Call options by funds: $1.67M | Put options by funds: $64.7M
Research analyst outlook
We haven’t received any recent analyst ratings for PPH.
Financial journalist opinion
Neutral
Seeking Alpha
2 weeks ago
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.
Neutral
Zacks Investment Research
3 weeks ago
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
The VanEck Pharmaceutical ETF (PPH) was launched on 12/20/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.
Positive
Zacks Investment Research
1 month ago
ETFs on the Move Post U.S.-China Trade Deal
Let's delve into the ETF world following the 90-day U.S.-China trade deal.
Positive
Zacks Investment Research
1 month ago
A Look at Pharma ETFs After Strong Q1 Earnings
Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.
Negative
Benzinga
1 month ago
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging volatility.
Neutral
Seeking Alpha
2 months ago
PPH: Will Overcome Tariffs, But Competitor Funds Look Stronger
VanEck Pharmaceutical ETF holds a mixed outlook due to high fees and tariff risks, warranting a hold rating despite strong top holdings. PPH's top holdings like Eli Lilly and Johnson & Johnson have diversified revenue streams and U.S. manufacturing investments, mitigating tariff impacts. PPH has underperformed compared to broader healthcare ETFs like VHT and XLV, which offer better diversification and lower expense ratios.
Neutral
Zacks Investment Research
2 months ago
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on 12/20/2011.
Neutral
Seeking Alpha
3 months ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?
Neutral
Zacks Investment Research
4 months ago
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund launched on 12/20/2011.
Positive
Seeking Alpha
5 months ago
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
Charts implemented using Lightweight Charts™